We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma.
Questions
1. What are the limitations of current first-line treatment strategies for advanced hepatocellular carcinoma? (0:05)
2. What is the rationale for combining cabozantinib with atezolizumab in this treatment setting? (0:54)
3. Could you tell us a little about the aims and design of the COSMIC-312 study? (1:41)
4. When are results expected from this study? (2:34)
5. What other combined immunotherapy approaches seem promising? (2:56)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Lorenza Rimassa has received lecture fees from AstraZeneca, AbbVie, Gilead, Roche; Advisory board/consulting role fees from Lilly, Bayer, Sirtex Medical, ArQule, Exelixis, Ipsen, Celgene, Eisai, Hengrui Therapeutics, MSD, Baxter, Amgen, Italfarmaco, Sanofi, Incyte; Travel expenses from ArQule and Ipsen.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
